Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
petosemtamab + pembrolizumab
- Development stage
- Phase 3
- Lead developer
- Merus
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Petosemtamab + pembrolizumab is an investigational combination therapy comprising petosemtamab (MCLA-158) and pembrolizumab (Keytruda) used in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), specifically in PD-L1–positive patients. Petosemtamab is a bispecific monoclonal antibody targeting both LGR5 and epidermal growth factor receptor (EGFR); it blocks EGF ligand binding, facilitates EGFR internalization and degradation in LGR5+ cells, and induces antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) via enhanced Fc receptor binding. Pembrolizumab is a monoclonal antibody that blocks programmed cell death protein 1 (PD-1), activating the immune system to target tumor cells. The combination is under investigation for superior efficacy compared to pembrolizumab alone, based on encouraging response rates and safety in early clinical studies.
- Other names
- petosemtamab + pembrolizumab
02
Targets
EGFR (Epidermal growth factor receptor)LGR5 (Leucine-rich repeat-containing G-protein coupled receptor 5)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on petosemtamab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on petosemtamab + pembrolizumab.